Oncologic theranostics: Recognition of this concept in antigen-directed cancer therapy for colorectal cancer with anti-TAG-72 monoclonal antibodies

Expert Review of Molecular Diagnostics

Volumn 11, Issue 7, 2011, Pages 667-670

  Povoski, Stephen P ^a   Hatzaras, Ioannis S ^a   Mojzisik, Cathy M ^b   Martin Jr , Edward W ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b Veeda Oncology   (United States)

Author keywords

antigen directed cancer therapy; colorectal cancer; monoclonal antibodies; multimodality; oncologic theranostics; TAG 72 antigen

Indexed keywords

IODINE 124; IODINE 125; MONOCLONAL ANTIBODY; TUMOR ANTIGEN; TUMOR ASSOCIATED GLYCOPROTEIN 72 ANTIGEN; TUMOR ASSOCIATED GLYCOPROTEIN 72 MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; COLORECTAL CANCER; FOLLOW UP; HUMAN; ISOTOPE LABELING; MOLECULARLY TARGETED THERAPY; ONCOLOGIC THERANOSTICS; PROGNOSIS; REVIEW; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; GLYCOPROTEINS; HUMANS;

EID: 80052766048     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/erm.11.54     Document Type: Review

References (41)

1. Gilham I. Theranostics: an emerging tool in drug discovery and commercialisation. Drug Discov. World 1(3), 17-23 (2002).
2. Johnson VG, Schlom J, Paterson AJ, Bennett J, Magnani JL, Colcher D. Analysis of a human tumor-associated glycoprotein (TAG-72) identified by monoclonal antibody B723 Cancer Res. 46(2), 850-857 (1986). (Pubitemid 16145448)
3. Thor A, Ohuchi N, Szpak CA, Johnston WW, Schlom J. Distribution of oncofetal antigen tumor-associated glycoprotein-72 defined by monoclonal antibody B723 Cancer Res. 46(6), 3118-3124 (1986). (Pubitemid 16074337)
4. Sheer DG, Schlom J, Cooper HL. Purification and composition of the human tumor-associated glycoprotein (TAG-72) defined by monoclonal antibodies CC49 and B723 Cancer Res. 48(23), 6811-6818 (1988). (Pubitemid 19012211)
5. Loy TS, Nashelsky MB. Reactivity of B723 with adenocarcinomas. An immunohistochemical study of 476 cases. Cancer 72(8), 2495-2498 (1993). (Pubitemid 23299617)
6. Povoski SP, Neff RL, Mojzisik CM et al. A comprehensive overview of radioguided surgery using gamma detection probe technology. World J. Surg. Oncol. 7, 11 (2009).
7. Sickle-Santanello BJ, O'Dwyer PJ, Mojzisik C et al. Radioimmunoguided surgery using the monoclonal antibody B723 in colorectal tumors. Dis. Colon Rectum 30(10), 761-764 (1987). (Pubitemid 17168043)
8. Hinkle GH, Nabi HA, Miller EA et al. Radioimmunodetection of implanted tumors with gamma probe. NCI Monogr. 3, 83-87 (1987). (Pubitemid 17010596)
9. Tuttle SE, Jewell SD, Mojzisik CM et al. Intraoperative radioimmunolocalization of colorectal carcinoma with a hand-held gamma probe and MAb B723: comparison of in vivo gamma probe counts with in vitro MAb radiolocalization. Int. J. Cancer 42(3), 352-358 (1988).
10. Martin EW Jr, Mojzisik CM, Hinkle GH et al. Radioimmunoguided surgery using monoclonal antibody. Am. J. Surg. 156(5), 386-392 (1988). (Pubitemid 19009745)
11. Nieroda CA, Mojzisik C, Sardi A et al. Staging of carcinoma of the breast using a hand-held gamma detecting probe and monoclonal antibody B723 Surg. Gynecol. Obstet. 169(1), 35-40 (1989). (Pubitemid 19194330)
12. Sardi A, Siddiqi MA, Hinkle GH et al. Localization by hand-held gamma probe of tumor labeled with antibody 'cocktail'. J. Surg. Res. 47(3), 227-234 (1989). (Pubitemid 19216178)
13. Nieroda CA, Mojzisik C, Sardi A et al. Radioimmunoguided surgery in primary colon cancer. Cancer Detect. Prev. 14(6), 651-656 (1990).
14. Nieroda CA, Mojzisik C, Hinkle G, Thurston MO, Martin EW Jr. Radioimmunoguided surgery (RIGS) in recurrent colorectal cancer. Cancer Detect. Prev. 15(3), 225-229 (1991).
15. Cohen AM, Martin EW Jr, Lavery I et al. Radioimmunoguided surgery using iodine 125 B723 in patients with colorectal cancer. Arch. Surg. 126(3), 349-352 (1991).
16. Martin EW Jr, Carey LC. Second-look surgery for colorectal cancer. The second time around. Ann. Surg. 214(3), 321-325; discussion 326-327 (1991).
17. Arnold MW, Schneebaum S, Berens A et al. Intraoperative detection of colorectal cancer with radioimmunoguided surgery and CC49, a second-generation monoclonal antibody. Ann. Surg. 216(6), 627-632 (1992).
18. Arnold MW, Schneebaum S, Berens A, Mojzisik C, Hinkle G, Martin EW Jr. Radioimmunoguided surgery challenges traditional decision making in patients with primary colorectal cancer. Surgery 112(4), 624-629; discussion 629-630 (1992).
19. Schneebaum S, Arnold MW, Houchens DP et al. The significance of intraoperative periportal lymph node metastasis identification in patients with colorectal carcinoma. Cancer 75(12), 2809-2817 (1995).
20. Bertsch DJ, Burak WE Jr, Young DC, Arnold MW, Martin EW Jr. Radioimmunoguided surgery improves survival for patients recurrent colorectalcancer. Surgery 118(4), 634-638; discussion 638-639 (1995).
21. Arnold MW, Young DC, Hitchcock CL, Schneebaum S, Martin EW Jr. Radioimmunoguided surgery in primary colorectal carcinoma: an intraoperative prognostic tool and adjuvant to traditional staging. Am. J. Surg. 170(4), 315-318 (1995).
22. Burak WE Jr, Schneebaum S, Kim JA et al. Pilot study evaluating the intraoperative localization of radiolabeled monoclonal antibody CC83 in patients with metastatic colorectal carcinoma. Surgery 118(1), 103-108 (1995).
23. Cote RJ, Houchens DP, Hitchcock CL et al. Intraoperative detection of occult colon cancer micrometastases using 125 I-radiolabled monoclonal antibody CC49 Cancer 77(4), 613-620 (1996).
24. Arnold MW, Hitchcock CL, Young DC, Burak WE Jr, Bertsch DJ, Martin EW Jr. Intra-abdominal patterns of disease dissemination in colorectal cancer identified using radioimmunoguided surgery. Dis. Colon Rectum 39(5), 509-513 (1996). (Pubitemid 26149421)
25. Bertsch DJ, Burak WE Jr, Young DC, Arnold MW, Martin EW Jr. Radioimmunoguided surgery for colorectal cancer. Ann. Surg. Oncol. 3(3), 310-316 (1996). (Pubitemid 126728997)
26. Hitchcock CL, Arnold MW, Young DC, Schneebaum S, Martin EW Jr. TAG-72 expression in lymph nodes and RIGS. Dis. Colon Rectum 39(4), 473-475 (1996).
27. Martin EW Jr, Thurston MO. The use of monoclonal antibodies (MAbs) and the development of an intraoperative hand-held probe for cancer detection. Cancer Invest. 14(6), 560-571 (1996). (Pubitemid 26423518)
28. Martinez DA, Barbera-Guillem E, LaValle GJ, Martin EW Jr. Radioimmunoguided surgery for gastrointestinal malignancies: an analysis of 14 years of clinical experience. Cancer Control 4(6), 505-516 (1997). (Pubitemid 28167817)
29. Bakalakos EA, Young DC, Martin EW Jr. Radioimmunoguided surgery for patients with liver metastases secondary to colorectal cancer. Ann. Surg. Oncol. 5(7), 590-594 (1998).
30. Arnold MW, Young DM, Hitchcock CL, Barberá-Guillem E, Nieroda C, Martin EW Jr. Staging of colorectal cancer: biology vs. morphology. Dis. Colon Rectum 41(12), 1482-1487 (1998). (Pubitemid 28565458)
31. Barbera-Guillem E, Arnold MW, Nelson MB, Martin EW Jr. First results for resetting the antitumor immune response by immune corrective surgery in colon cancer. Am. J. Surg. 176(4), 339-343 (1998). (Pubitemid 28512624)
32. Sun D, Bloomston M, Hinkle G et al. Radioimmunoguided surgery (RIGS), PET/CT image-guided surgery, and fluorescence image-guided surgery: past, present, and future. J. Surg. Oncol. 96(4), 297-308 (2007). (Pubitemid 47509764)
33. Povoski SP, Hatzaras IS, Mojzisik CM et al. Intraoperative antigen-directed cancer surgery for primary colorectal cancer: 15-year survival analysis. Ann. Surg. Oncol. DOI: 101245/s10434-011-1880-3 (2011) (Epub ahead of print).
34. Agnese DM, Abdessalam SF, Burak WE et al. Pilot study using a humanized CC49 monoclonal antibody (HuCC49δCH2) to localize recurrent colorectal carcinoma. Ann. Surg. Oncol. 11(2), 197-202 (2004). (Pubitemid 40486796)
35. Fang L, Holford NH, Hinkle G et al. Population pharmacokinetics of humanized monoclonal antibody HuCC49DδCH2 and murine antibody CC49 in colorectal cancer patients. J. Clin. Pharmacol. 47(2), 227-237 (2007). (Pubitemid 46146489)
36. H2 for TAG-72 antigen-directed positron emission tomography (PET) imaging of LS174T colon adenocarcinoma tumor implants in xenograft mice: preliminary results. World J. Surg. Oncol. 8, 65 (2010).
37. Holland JP, Sheh Y, Lewis JS. Standardized methods for the production of high specific-activity zirconium-89 Nucl. Med. Biol. 36(7), 729-739 (2009).
38. van Dongen GA, Vosjan MJ. Immuno-positron emission tomography: shedding light on clinical antibody therapy. Cancer Biother. Radiopharm. 25(4), 375-385 (2010).
39. McCabe KE, Wu AM. Positive progress in ImmunoPET - not just a coincidence. Cancer Biother. Radiopharm. 25(3), 253-261 (2010).
40. Anderson CJ, Ferdani R. Copper-64 radiopharmaceuticals for PET imaging of cancer: advances in preclinical and clinical research. Cancer Biother. Radiopharm. 24(4), 379-393 (2009).
41. Shokeen M, Anderson CJ. Molecular imaging of cancer with copper-64 radiopharmaceuticals and positron emission tomography (PET).Acc. Chem. Res. 42(7), 832-841 (2009).